Related Experiment Video

Updated: Aug 18, 2026

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

[The coagulation cascade--clinical implications]

Harald Langer1, Meinrad Gawaz

  • 1Medizinische Klinik und Poliklinik, Abteilung III, Universitätsklinikum Tübingen, Eberhard-Karls-Universität Tübingen, Tübingen.

Herz
|May 20, 2005
PubMed

Insights

This study reviews anticoagulant strategies for patients undergoing percutaneous coronary intervention (PCI). It highlights the use of unfractionated heparin (UFH) and low-molecular-weight heparins (LMWH) for preventing ischemic events.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Cardiology

Context:

  • Coronary artery disease (CAD) patients undergoing percutaneous coronary intervention (PCI) have an activated coagulation system.
  • Preventing ischemic events in these patients requires effective anticoagulant strategies.
  • Primary hemostasis involves platelet-rich thrombus formation, while secondary hemostasis leads to fibrin formation.

Purpose:

  • To review the role of anticoagulants in patients undergoing PCI.
  • To compare unfractionated heparin (UFH) and low-molecular-weight heparins (LMWH) in this setting.

Summary:

  • The coagulation system is a complex cascade with various therapeutic inhibition points.
  • Unfractionated heparin (UFH) is a standard intravenous anticoagulant therapy during PCI.
  • Low-molecular-weight heparins (LMWH) are increasingly utilized due to favorable pharmacodynamic properties, though their comparative efficacy to UFH requires further evaluation.

Impact:

  • Informs clinical decisions regarding anticoagulant selection for PCI patients.
  • Highlights the need for further research to fully evaluate LMWH versus UFH.
  • Contributes to optimizing therapeutic strategies for preventing ischemic complications in cardiovascular interventions.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Coagulation01:06

Coagulation

Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...